Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
Altamira Therapeutics (Nasdaq: CYTO) announced that its Bentrio® nasal spray for allergic rhinitis has been successfully tested for the absence of over 230 prohibited substances listed by the World Anti-Doping Agency (WADA). This confirmation enhances Bentrio's suitability for athletes who need to comply with anti-doping regulations while protecting themselves against airborne allergens or particles.
The drug-free and preservative-free nasal spray forms a protective barrier on the nasal mucosa, making it inherently suitable for athletes. The rigorous screening by a leading anti-doping laboratory further validates its compliance with anti-doping regulations, addressing the challenges athletes face in managing allergies without risking positive doping test results.
Altamira Therapeutics (Nasdaq: CYTO) ha annunciato che il suo spray nasale Bentrio® per rinite allergica è stato testato con successo per l'assenza di oltre 230 sostanze proibite elencate dalla World Anti-Doping Agency (WADA). Questa conferma aumenta l'idoneità di Bentrio per gli atleti che devono rispettare le normative anti-doping, proteggendosi al contempo dagli allergeni o dalle particelle trasportate dall'aria.
Lo spray nasale, privo di farmaci e conservanti, forma una barriera protettiva sulla mucosa nasale, rendendolo intrinsecamente adatto per gli atleti. Lo screening rigoroso da parte di un laboratorio anti-doping di primo livello valida ulteriormente la sua conformità alle normative anti-doping, affrontando le sfide che gli atleti devono affrontare nella gestione delle allergie senza rischiare risultati positivi ai test antidoping.
Altamira Therapeutics (Nasdaq: CYTO) anunció que su spray nasal Bentrio® para rinitis alérgica ha sido probado con éxito por la ausencia de más de 230 sustancias prohibidas listadas por la Agencia Mundial Antidopaje (WADA). Esta confirmación mejora la idoneidad de Bentrio para los atletas que necesitan cumplir con las regulaciones antidopaje mientras se protegen contra alérgenos o partículas en el aire.
El spray nasal, libre de fármacos y conservantes, forma una barrera protectora en la mucosa nasal, lo que lo hace intrínsecamente adecuado para los atletas. La rigurosa evaluación por parte de un laboratorio antidopaje líder valida aún más su conformidad con las regulaciones antidopaje, abordando los desafíos que enfrentan los atletas para gestionar las alergias sin arriesgar resultados positivos en las pruebas de doping.
Altamira Therapeutics(Nasdaq: CYTO)는 알레르기 비염 치료를 위한 Bentrio® 비강 스프레이가 세계 반도핑 기구(WADA)에서 규정한 230가지 이상의 금지 물질이 없음을 성공적으로 테스트했다고 발표했습니다. 이 확인은 공기 중 알레르겐이나 입자로부터 자신을 보호하면서 반도핑 규정을 준수해야 하는 운동선수에게 Bentrio의 적합성을 높입니다.
약물이 없고 방부제가 없는 이 비강 스프레이는 비강 점막에 보호 장벽을 형성하여 본질적으로 운동선수에게 적합합니다. 선도적인 반도핑 실험실에 의한 철저한 검증은 반도핑 규정 준수를 더욱 확인해 주며, 운동선수들이 긍정적인 도핑 테스트 결과를 리스크 없이 알레르기를 관리하는 도전 과제를 해결하는 데 도움을 줍니다.
Altamira Therapeutics (Nasdaq: CYTO) a annoncé que son spray nasal Bentrio® pour rhinite allergique a été testé avec succès pour l'absence de plus de 230 substances interdites répertoriées par l'Agence mondiale antidopage (WADA). Cette confirmation renforce l'adéquation de Bentrio pour les athlètes qui doivent se conformer aux règlements antidopage tout en se protégeant contre les allergènes ou les particules présentes dans l'air.
Ce spray nasal, sans médicament et sans conservateur, forme une barrière protectrice sur la muqueuse nasale, le rendant intrinsèquement adapté aux athlètes. Le dépistage rigoureux par un laboratoire antidopage de premier plan valide davantage sa conformité aux règlements antidopage, répondant ainsi aux défis auxquels les athlètes doivent faire face pour gérer les allergies sans risquer des résultats positifs aux tests de dopage.
Altamira Therapeutics (Nasdaq: CYTO) hat angekündigt, dass sein Nasenspray Bentrio® gegen allergische Rhinitis erfolgreich auf das Fehlen von über 230 von der Welt-Anti-Doping-Agentur (WADA) aufgeführten verbotenen Substanzen getestet wurde. Diese Bestätigung erhöht Bentrio's Eignung für Sportler, die die Anti-Doping-Vorschriften einhalten müssen und sich gleichzeitig vor luftgetragenen Allergenen oder Partikeln schützen möchten.
Das drogen- und konservierungsmittelfreie Nasenspray bildet eine schützende Barriere auf der Nasenschleimhaut, was es grundsätzlich für Sportler geeignet macht. Die strenge Überprüfung durch ein führendes Anti-Doping-Labor validiert zusätzlich die Einhaltung der Anti-Doping-Vorschriften und geht auf die Herausforderungen ein, denen Sportler gegenüberstehen, wenn sie Allergien ohne Risiko positiver Dopingtestergebnisse managen müssen.
- Bentrio nasal spray tested negative for over 230 WADA-prohibited substances
- Product confirmed suitable for athletes complying with anti-doping regulations
- Addresses a significant market need for allergy relief among athletes
- None.
Insights
The confirmation of Bentrio's absence of prohibited substances is a positive development for Altamira Therapeutics. This news enhances the product's market potential, particularly among athletes who face strict anti-doping regulations. The comprehensive testing for over 230 prohibited substances adds credibility to Bentrio's safety profile.
From a medical perspective, Bentrio's drug-free and preservative-free formulation aligns well with the growing demand for natural and side-effect-free treatments. Its mechanism of action, forming a protective barrier on the nasal mucosa, offers a unique approach to allergic rhinitis management without the risk of drug interactions or doping violations.
However, investors should note that while this news strengthens Bentrio's position in the sports medicine market, its overall impact on Altamira's financial performance may be in the short term. The company will need to effectively market this advantage to see significant revenue growth from the athlete segment.
This announcement positions Bentrio favorably in the sports medicine and allergy treatment markets. The product's confirmed suitability for athletes addresses a specific niche with high compliance requirements, potentially leading to increased adoption among professional and amateur athletes alike.
The market opportunity is significant, considering the prevalence of allergic rhinitis among athletes and the challenges they face in finding compliant treatments. Bentrio's unique selling proposition as a drug-free, WADA-compliant nasal spray could drive market penetration and brand loyalty.
However, Altamira must now focus on strategic marketing and distribution to capitalize on this advantage. Partnerships with sports organizations, teams and influential athletes could be important for driving awareness and adoption. The company should also consider the potential for expansion into broader consumer markets, leveraging the product's safety profile as a key differentiator.
Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) --
- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of them
- Outcome further confirms Bentrio’s suitability for use by athletes in protection against airborne allergens or other particles
Altamira Medica Ltd. (“Altamira” or the “Company”), an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), today announced that its preservative-free, drug-free Bentrio® nasal spray for allergic rhinitis was tested successfully for the absence of more than 230 prohibited substances listed by the World Anti-Doping Agency (WADA). This finding further confirms Bentrio’s suitability for athletes who must comply with antidoping regulations but at the same time need to protect themselves against airborne allergens or other particles.
“Many athletes have to walk a tightrope when seeking to legitimately prevent allergic rhinitis or find relief from allergy symptoms while avoiding inadvertent conflicts with antidoping regulations”, commented Thomas Meyer, Altamira's founder, Chairman, and CEO. “With today’s sensitive analytical methods, athletes may for example trigger positive doping test results when taking treatments or supplements which are contaminated with prohibited substances. Or in other cases, the treatment or supplement may contain a substance which is permitted when taken with certain products, but prohibited when taken in other forms, e.g. through a different administration route.”
The case of Lennert Van Eetvelt, a young professional Belgian cyclist, illustrates the possible consequences of testing inadvertently positive for a prohibited substance.1 In 2023, Van Eetvelt was temporarily placed on non-active racing status for ‘alleged breach of anti-doping laws’ after AFLD, the French anti-doping authority, had decided to investigate his (declared) use of an allergy nasal spray. His treatment contained a substance which is banned when taken in pill-form or via an injection but permitted when taken in spray form. The cyclist was ultimately cleared of the allegation, but the inquiry had shut him out of competitions for three weeks.
Mr. Meyer added: “By its design as a drug-free and preservative-free nasal spray which acts by forming a protective barrier on the nasal mucosa, and by the choice of ingredients, Bentrio is already well suited for compliant use by athletes. The rigorous screening of Bentrio for a standard panel of prohibitive substances by one of the world’s leading anti-doping laboratories, which showed negative results across the board, further confirms its suitability for athletes.”
About Bentrio
Bentrio is an “over the counter” drug-free nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of airborne particles with cells; in addition, the composition serves to bind such particles and help with their discharge. The efficacy and safety of Bentrio has been demonstrated in a total of four clinical trials, of which the largest one (“NASAR” study) enrolled 100 patients suffering from seasonal allergic rhinitis. In NASAR, participants self-administered either Bentrio or saline nasal spray for two weeks 3 x per day. The study showed a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013), as well as a statistically highly significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001). In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment. For more information, visit: www.bentrio.com
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
FAQ
What did recent testing reveal about Altamira Therapeutics' Bentrio nasal spray?
How does Bentrio nasal spray work to protect against allergies?
Why is Bentrio's WADA compliance important for athletes?
What advantages does Bentrio offer over other allergy treatments for athletes?
